Department of Pharmacology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.
Fellow, Cornea and External Eye Diseases, Department of Ophthalmology, Minto Ophthalmic Hospital, RIO, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.
Indian J Ophthalmol. 2021 Feb;69(2):257-261. doi: 10.4103/ijo.IJO_2083_20.
To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergic conjunctivitis.
This is a prospective, observer-masked, comparative study of 180 patients with mild to moderate allergic conjunctivitis, randomized into three groups of 60 patients each. Each group was assigned to be treated with one of the three treatment options namely Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% ophthalmic solutions. Patients were followed-up at regular intervals with relief and resolution of symptoms and signs noted using Total Ocular Scoring System (TOSS) and hyperaemia scale.
All three topical medications were effective in resolving symptoms of the patients with mild to moderate allergic conjunctivitis. Baseline mean TOSS scores for Alcaftadine group, Olopatadine group and Bepotastine besilate group were (7.68±2.32), (7.65±2.32) and (7.45±2.27) respectively as compared to the corresponding TOSS scores on 14 Day (4 visit) which were (0.2 ± 0.43), (0.4 ± 0.56) and (0.1 ± 0.36) respectively. The resolution of symptoms in the Bepotastine and Alcaftadine groups was significantly profound as compared to the Olopatadine group (p = 0.008). Bepotastine and Alcaftadine groups significantly reduced allergic conjunctivitis symptoms compared to Olopatadine group (p = 0.008).
All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis. However, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the symptoms of allergic conjunctivitis.
比较盐酸奥洛他定 0.2%、盐酸左卡巴斯汀 0.25%和贝他斯汀 1.5%滴眼液治疗过敏性结膜炎的疗效和安全性。
这是一项前瞻性、观察者盲法、比较研究，纳入 180 例轻中度过敏性结膜炎患者，随机分为 3 组，每组 60 例。每组分别给予盐酸奥洛他定 0.2%、盐酸左卡巴斯汀 0.25%和贝他斯汀 1.5%滴眼液治疗。定期随访患者，记录总眼评分系统（TOSS）和充血评分缓解和消退情况。
三种局部用药均能有效缓解轻中度过敏性结膜炎患者的症状。盐酸左卡巴斯汀组、盐酸奥洛他定组和贝他斯汀组的基线 TOSS 评分分别为（7.68±2.32）、（7.65±2.32）和（7.45±2.27），而第 14 天（第 4 次就诊）的 TOSS 评分分别为（0.2±0.43）、（0.4±0.56）和（0.1±0.36）。贝他斯汀组和盐酸左卡巴斯汀组的症状缓解程度明显优于盐酸奥洛他定组（p=0.008）。与盐酸奥洛他定组相比，贝他斯汀组和盐酸左卡巴斯汀组均能显著减轻过敏性结膜炎症状（p=0.008）。
研究中使用的三种局部眼用药物均安全有效，治疗过敏性结膜炎。然而，贝他斯汀和盐酸左卡巴斯汀在缓解过敏性结膜炎症状方面似乎优于盐酸奥洛他定。
